CAR T cell therapy for solid tumors: Fatal attraction requires adhesion
- PMID: 35690053
- DOI: 10.1016/j.medj.2022.05.009
CAR T cell therapy for solid tumors: Fatal attraction requires adhesion
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors in clinical studies in contrast to hematological malignancies. In a paper recently published in Nature, Larson et al. report that CAR T cell activity against solid tumors depends on cell adhesion mediated by IFNγ signaling, opening the prospect of improving their clinical activity in the future.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.B. and S.G. have patent applications in the fields of cell and/or gene therapy for cancer. S.G. is a consultant of TESSA Therapeutics, a DSMB member of Immatics, and has received honoraria from Tidal, Catamaran Bio, Sanofi, and Novartis within the last 2 years. None of these relationships conflict with the published work.
Comment on
-
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13. Nature. 2022. PMID: 35418687
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical